Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2575

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 2575
---
(1,819,514)
  
    Fixed assets 
     929,346 
  
    Acquired in-process research and development 
     45,640,000 
  
    Net assets acquired 
     45,713,687 
  
    Loss on consolidation of VIE 
     4,836,216 
  
    Total purchase price 
    $50,549,903 

In connection with the Merger,
the transactions that occurred concurrently with the closing date of the Merger were reflected “on the line”. “On the
line” describes those transactions triggered by the consummation of the Merger that are not recognized in the consolidated financial
statements of the Predecessor nor the Company as they are not directly attributable to either period but instead were contingent on the
Merger. The opening cash balance in the consolidated statement of cash flow of $1.88 million consists of $0.92 million from PBAX and $0.96
million from Predecessor. The number of shares of Common Stock issued and amounts recorded on the line within stockholders’ deficit
are reflected below to arrive at the opening consolidated balance sheet of the Company.

F-14

    Convertible  

    Preferred Stock  
    Series A  
    Additional  
    Stock  

    Series A  
    Common Stock  
    Paid-in  
    Subscription  
    Accumulated  

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Total 
  
    PBAX Closing Equity as of February 13, 2024 
     -  
    $-  
     54,812  
    $6  
    $541  
    $-  
    $(12,709,426) 
    $(12,708,879)
  
    Forfeiture of founders shares 
     -  
     -  
     (8,750) 
     (1) 
     1  
     -  
     -  
     - 
  
    Adjusted shares outstanding 
     -  
     -  
     46,062  
     5  
     542  
     -  
     (12,709,426) 
     (12,708,879)
  
    Shares issued as consideration in the Merger 
     -